Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10231780 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29399489 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL20825662 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL178780 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL178788 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL13697519 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29398335 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL178777 | 0.99 | CASP3 (0.49) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL17256393 | 0.99 | CASP3 (0.49) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL30291644 | 0.99 | CASP3 (0.49) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | GENENTECH, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4244219-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | Genentech, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4244218-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | Genentech, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783183-A | 1- (2- (4-cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxy-N- (benzyl) pyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anemia and cancer | 基因泰克公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-6759420-B1 | LOW MOLECULAR WEIGHT, FACTOR XA SPECIFIC BLOOD CLOTTING INHIBITORS WITHOUT SIDE EFFECTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| CN-1406226-A | Novel malonic acid derivatives, process for their preparation, their use as inhibitors of factor XA activity and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-03-26 | — | — | CN | disclosed |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-02-21 | — | — | US | disclosed |
| CN-1332723-A | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2002-01-23 | — | — | CN | disclosed |
| EP-1127884-A1 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| EP-1022268-A1 | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2000-07-26 | — | — | EP | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | F12, ME1, F11 | MDM4 4683/4885TP53 4819/4885CASP3 4390/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MDM4 3536/4885TP53 2216/4885CASP3 1273/4885 |
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | VHL, HIF1AN, EGLN2 | MDM4 2783/4885TP53 24/4885CASP3 2564/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | MDM4 4684/4885TP53 1916/4885CASP3 1499/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | MDM4 794/4885TP53 410/4885CASP3 4334/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | MDM4 4684/4885TP53 1916/4885CASP3 1499/4885 |
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | VHL, HIF1AN, FANCI | MDM4 896/4885TP53 29/4885CASP3 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.